Chemodenervation with botulinumtoxin in masseteric hypertrophy. Results of a treatment series;Die Chemodenervation mit Botulinumtoxin bei Masseterhypertrophie. Ergebnisse einer Behandlungsserie

Mund-, Kiefer- und Gesichtschirurgie

Volumn 9, Issue 2, 2005, Pages 101-108

  Mischkowski, R A ^a   Siessegger, M ^b   Lazar, F ^a   Zoller J E ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Aesthetische medizin koeln   (Germany)

Author keywords

Botulinum toxin; Chemodenervation; Clostridium botulinum; Masseteric hypertrophy; Massetric muscle

Indexed keywords

BOTULINUM TOXIN;

ARTICLE; CLINICAL ARTICLE; CLOSTRIDIUM BOTULINUM; CONSERVATIVE TREATMENT; DRUG CHOICE; FACE ASYMMETRY; HUMAN; MASSETER MUSCLE; MUSCLE DENERVATION; MUSCLE HYPERTROPHY; PATIENT CARE; RISK REDUCTION; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BOTULINUM TOXIN TYPE A; FOLLOW-UP STUDIES; HUMANS; HYPERTROPHY; INJECTIONS, INTRAMUSCULAR; MALE; MALOCCLUSION; MASSETER MUSCLE; MIDDLE AGED; MUSCLE DENERVATION; TREATMENT OUTCOME;

EID: 15944412114     PISSN: 14329417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10006-005-0601-0     Document Type: Article

References (25)

1. Addante RR (1994) Masseter muscle hypertrophy: Report of case and literature review. J Oral Maxillofac Surg 52: 1199-1202
2. Beckers HL (1977) Masseteric muscle hypertrophy and its intraoral surgical correction. J Maxillofac Surg 5: 28-35
3. Dressler D (2000) Complete secondary botulinum toxin therapy failure in blepharospasm. J Neurol 247: 809-810
4. Dressler D, Benecke R (2004) Antikörpervermitteltes Versagen der Botulinumtoxin-Therapie. In: Laskawi R, Roggenkämper P (Hrsg) Botulinumtoxin-Therapie im Kopf-Hals-Bereich. Urban & Vogel, München, S 58-70
5. Dressler D, Dirnberger G (2000) Botulinumtoxin therapy: Risk factors for therapy failure. Mov Disord 15 (Suppl 2): 51
6. Gobel H, Jost WH (2003) Botulinum-Toxin in der speziellen Schmerztherapie. Schmerz 17: 149-165
7. Hui AC (2002) Botulinum toxin for treatment of masseteric hypertrophy. J Neurol 249: 345
8. Kessler KR, Skutta M, Benecke R (1999) Long-term treatment of cervical dystonia with botulinum toxin A: Efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol 246: 265-274
9. Kim HJ, Yum KW, Lee SS, Heo MS, Seo K (2003) Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement. Dermatol Surg 29: 484-489
10. Kreyden OP, Geiges ML, Boni R, Burg G (2000) Botulinumtoxin: Vom Gift zum Medikament. Ein historischer Rückblick. Hautarzt 51: 733-737
11. Lindern JJ von, Niederhagen B, Appel T, Berge S, Reich RH (2001) Type A botulinum toxin for the treatment of hypertrophy of the masseter and temporal muscles: An alternative treatment. Plast Reconstr Surg 107: 327-332
12. Mandel L, Tharakan M (1999) Treatment of unilateral masseteric hypertrophy with botulinum toxin: Case report. J Oral Maxillofac Surg 57: 1017-1019
13. Manisali M, Amin M, Aghabeigi B, Newman L (2003) Retromandibular approach to the mandibular condyle: A clinical and cadaveric study. Int J Oral Maxillofac Surg 32: 253-256
14. Marx RE, Stern D (2002) Inflammatory, reactive, and infectious diseases. In: Marx RE, Stern D (Hrsg) Oral and maxillofacial pathology. Quintessenz, Berlin, pp 31-32
15. Moore AP, Wood GD (1994) The medical management of masseteric hypertrophy with botulinum toxin type A. Br J Oral Maxillofac Surg 32: 26-28
16. Naumann M (2003) Botulinumtoxin - Wirkprinzip und klinische Anwendung. Uni-Med, Bremen
17. Nishida M, Iizuka T (1995) Intraoral removal of the enlarged mandibular angle associated with masseteric hypertrophy. J Oral Maxillofac Surg 53: 1476-1479
18. Nishioka GJ, Montgomery MT (1988) Masticatory muscle hyperactivity in temporomandibular disorders: Is it an extrapyramidally expressed disorder? J Am Dent Assoc 116: 514-520
19. Park MY, Ahn KY, Jung DS (2003) Botulinum toxin type A treatment for contouring of the lower face. Dermatol Surg 29: 477-483
20. Roncevic R (1986) Masseter muscle hypertrophy. Aetiology and therapy. J Maxillofac Surg 14: 344-348
21. Smyth AG (1994) Botulinum toxin treatment of bilateral masseteric hypertrophy. Br J Oral Maxillofac Surg 32: 29-33
22. To EW, Ahuja AT, Ho WS et al (2001) A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic and electromyographic measurement. Br J Plast Surg 54: 197-200
23. Wood GD (1982) Masseteric hypertrophy and its surgical correction. Br Dent J 152: 416-417
24. Yonetsu K, Nakayama E, Yuasa K, Kanda S, Ozeki S, Shinohara M (1998) Imaging findings of some buccomasseteric masses. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 86: 755-759
25. Zachariades N, Rallis G, Papademetriou J, Konsolaki E, Markaki S, Mezitis M (1991) Phleboliths. A report of three unusual cases. Br J Oral Maxillofac Surg 29: 117-119